Kamada Sees Double-Digit Growth with Plasma-Derived Therapeutics Strategy

Kamada Ltd., a biopharma specialist focused on plasma-derived therapeutics, reported robust financial results for 2024 and projected continued growth in 2025. The company achieved an annual revenue of $161 million, a 13% increase from the previous year, and announced a special cash dividend of 20 cents per share.

The company's financial performance highlights include a 42% increase in adjusted EBITDA to $34.1 million and a net income of $14.5 million, representing a 75% boost from the prior year. Kamada expects to maintain its growth trajectory, with projected 2025 revenue between $178 million and $182 million, representing approximately 12% year-over-year expansion.

Key growth drivers include six FDA-approved plasma-derived specialty therapies, such as KEDRAB for rabies exposure and CYTOGAM for preventing cytomegalovirus complications in organ transplant patients. The company is also expanding its biosimilar portfolio in Israel, with plans to launch 1-3 products annually, potentially generating $15-20 million in sales within five years.

Strategically, Kamada is broadening its global footprint, recently securing a $25 million contract to supply rabies and anti-varicella treatments in South America from 2025 to 2027. The company is simultaneously pursuing strategic mergers, acquisitions, and business development opportunities to accelerate revenue growth.

An additional focus is expanding plasma collection operations, with a new facility in San Antonio, Texas expected to contribute $8-10 million annually and reduce reliance on third-party plasma suppliers. The company is also advancing a phase 3 trial for an inhaled alpha-1 antitrypsin therapy, which could address a market potential exceeding $2 billion.

Kamada's comprehensive strategy positions the company for continued growth in the specialized plasma-derived therapeutics market, leveraging its innovative product portfolio and strategic expansion efforts.